系统性自身免疫性风湿性疾病的I型干扰:发病原因,临床特征和治疗选择
Konstantinos Drougkas1, Charalampos Skarlis1, Clio Mavragani1,2
1Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Mediterranean journal of rheumatology
|August 28, 2024
概括
I型干扰素 (IFN) 途径失调是系统性自身免疫性类风湿性疾病 (SARD) 的关键. 了解国际金融机构的IFN.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 遗传学 是一个遗传学.
背景情况:
- I型干扰素 (IFN) 途径失调与系统性自身免疫性类风湿性疾病 (SARDs) 的病原发生有关.
- 遗传和表观遗传因素有助于自身免疫性疾病中异常的I型IFN反应.
- 改变的I型IFN产生与SARDs的临床表型,疾病活性,严重程度和治疗反应相关.
研究的目的:
- 审查I型IFN在系统性自身免疫性疾病中的作用.
- 专注于SARS中I型IFN的病理生理学,临床和治疗方面的研究.
主要方法:
- 关于I型干扰素在系统性自身免疫性疾病中的作用的文献综述.
- 综合有关遗传,表观遗传和临床关联的信息.
- 治疗影响的分析.
主要成果:
- 第一种类型的IFN通路失调是SLE,RA,SjD,SSc和DM等SARD的共同特征.
- 异常的I型IFN签名与疾病特征和治疗结果有关.
- 遗传和表观遗传改变是这些失调的关键驱动因素.
结论:
- 第一种类型的IFN是多种SARDs病原体中的关键参与者.
- 准I型IFN通路为SARDs提供了潜在的治疗策略.
- 对IFN向治疗的进一步研究是有必要的.
相关概念视频
T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963
Autoimmune Disorders
398
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
398
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


